PT. RICHMOND, Calif., Oct. 8 Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical company, announced today thatThomas P. Soloway, Senior Vice President and Chief Financial Officer, isscheduled to present at the Natixis Bleichroeder Second Annual Hidden GemsConference in New York City on Monday, October 13, 2008 at 9:30 AM EasternTime.
An audio webcast of the presentation will be available athttp://www.wsw.com/webcast/nblr2/transcept/ and on the Transcept website athttp://www.transcept.com. The replay of the presentation will be availablefor 30 days.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals is a specialty pharmaceutical company focused onthe development and commercialization of proprietary products that addressimportant therapeutic needs in the fields of psychiatry and sleep medicine.The lead Transcept product candidate, Intermezzo(R), is a sublingual low doseformulation of zolpidem that has been developed for use as-needed for thetreatment of insomnia when a middle of the night awakening is followed bydifficulty returning to sleep. Phase 3 clinical trials have been completedfor Intermezzo(R) and, on September 30, 2008, Transcept submitted a New DrugApplication to the U.S. Food and Drug Administration.For further information, please visit the company's website at:http://www.transcept.com.
This press release contains forward-looking statements for purposes of thePrivate Securities Litigation Reform Act of 1995 (the "Act"). Transceptdisclaims any intent or obligation to update these forward-looking statements,and claim the protection of the Safe Harbor for forward-looking statementscontained in the Act. Examples of such statements include, but are not limitedto, the expected benefits of Transcept product candidates. Such statements arebased on management's current expectations, but actual results may differmaterially due to various risks and uncertainties, including, but not limitedto, Transcept product candidates may have unexpected adverse side effects orinadequate therapeutic efficacy; positive results in clinical trials may notbe sufficient to obtain FDA approval; physician or patient reluctance to useIntermezzo(R), if approved; potential alternative therapies; maintainingadequate patent or trade secret protection without violating the intellectualproperty rights of others; and other difficulties or delays in, clinicaldevelopment, obtaining regulatory approval, market acceptance andcommercialization of Transcept product candidates.Transcept Pharmaceuticals, Inc. Michael Gill Director of Communications (510) 215-3575 firstname.lastname@example.org The Ruth Group Investors / Media Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 email@example.com firstname.lastname@example.org
SOURCE Transcept Pharmaceuticals, Inc.